Crohn Disease Pathology
No Results
No Results
processing….
Crohn disease (CD) is an idiopathic, chronic regional enteritis that most commonly affects the terminal ileum but has the potential to affect any part of the gastrointestinal tract from mouth to anus. This condition was first described by Crohn, Ginzburg, and Oppenheimer in 1932, but it was not clinically, histologically, or radiographically distinguished from ulcerative colitis (UC) until 1959. [1, 2]
Untreated CD is characterized by transmural (full-thickness) inflammation, involvement of discontinuous segments of the intestine (skip areas), and, in a proportion of cases, by non-necrotizing granulomas composed of epithelioid histiocytes. Patients present with a range of symptoms, including crampy abdominal pain and diarrhea, which may be complicated by intestinal fistulas, particularly after surgical intervention, by intramural abscesses, and by bowel obstruction.
The diagnosis of CD can be difficult, and the proper clinical separation of this entity from UC has important therapeutic implications. [3] Consequently, a thorough understanding of the clinical, radiologic, endoscopic, and pathologic features of CD, as well as effective communication between the pathologist and the managing clinicians, is essential to diagnostic accuracy.
Below are examples of some gross features of Crohn disease.
See Crohn Disease and Imaging in Crohn Disease for more information on these topics.
The prevalence of Crohn disease (CD) ranges from 26 to 199 cases per 100,000 persons [4] and is more commonly seen in white individuals living in Western industrialized nations. [5, 4] In the United States, approximately 201 per 100,000 persons are affected; those of European (Ashkenazi) Jewish heritage have a 2-4 times higher prevalence than members of the general population. [6]
The incidence and prevalence of the disease (especially colonic CD) are steadily increasing, mainly in northern climates and urban areas, but CD is also becoming more common in regions such as Africa, South America, and Asia. [5] Although this condition can occur at any age, there are 2 peaks of incidence, one in early adulthood (range, teens–20s) and another in the 60-70 year age group. Males and females are affected, but there is a slight female predilection for the disease.
The precise etiology of Crohn disease (CD) is unknown, but there are several known risk factors, including family history, smoking, use of oral contraceptives, diet, and ethnicity. A combination of factors, including aberrant mucosal immune responses, intestinal epithelial dysfunction, and defects of host interactions with intestinal microbes likely contribute to CD. [7, 8]
There is a clear genetic predisposition for Crohn disease. First-degree relatives have a 13-18% increase in incidence, and there are concordance rates of 50% in monozygotic twins. Classic Mendelian inheritance is not seen, implying a polygenic basis of the disease. [9, 10]
Molecular linkage analyses of affected families have identified NOD2 (nucleotide-binding domain 2) as a susceptibility gene in CD. [11, 12] NOD2 encodes a protein that binds to intracellular bacterial peptidoglycans, subsequently activates NF-kB (nuclear factor-kappaB), and may be involved both in preventing excessive immune activation and in combating luminal microbes. However, fewer than 10% of individuals carrying NOD2 mutations develop the disease, and genomic screening has identified linkage to multiple chromosomes, including chromosomes 3, 7, 12, and 16. [13, 14, 15]
Other genes of interest include ATG16L1 (autophagy-related 16-like) and IRGM (immunity-related GTPase M), both of which are involved in autophagy and the clearance of intracellular bacteria. IL23R (interleukin-23 receptor) may also be involved, as it is a regulatory cytokine receptor that plays a role in the initiation of the innate and adaptive immune activation in the intestinal mucosa. [16, 17, 18, 19]
See Crohn Disease and NOD2/CARD15 for more information on this topic.
Environmental factors, especially cigarette smoking and diet, are also clearly involved in this disease. Tobacco smoking doubles the risk of both initial and recurrent Crohn disease (CD), unlike the apparent protective effect of tobacco seen in ulcerative colitis. Improved food storage conditions and decreased food contamination may also contribute to the increase in incidence. [20]
This so-called “hygiene hypothesis” suggests that the reduction in enteric infections in developed countries has resulted in inadequate development of the regulatory processes that limit mucosal immune responses. [21] Pathogens that otherwise might cause only self-limited disease instead may trigger overwhelming inflammatory responses in susceptible individuals. Although more data are required, the observations that episodes of acute gastritis often precede the onset of CD in humans and that helminthic infections can prevent disease development in animal models lend support to this idea. [21]
Given the success of treatment of peptic ulcer disease with the discovery of Helicobacter pylori as the causative agent, there have been multiple studies attempting to link an infectious agent with inflammatory bowel disease (IBD). [22] Although decreased numbers of native lactobacilli and overgrowth of enteric bacteria are postulated to trigger excessive inflammation seen in Crohn disease (CD), a single causative infectious agent has not been identified. Mycobacteria have been studied extensively in this context, given the histopathologic similarities between intestinal tuberculosis and CD, but the suggestion that mycobacteria play an etiologic role has been largely disputed. [23, 24]
Similarly, although both a measleslike virus and the measles vaccine have been implicated in the pathogenesis of CD, epidemiologic evidence has failed to support either as a causative agent. [25, 26, 27, 28] The search for an infectious cause of IBD continues, but it seems more likely that the ultimate cause is polyfactorial. [7]
A variety of epithelial defects have been described in both Crohn disease (CD) and ulcerative colitis, including tight junction barrier function, defective transepithelial transport, extracellular matrix barrier proteins, and Paneth cell antibacterial peptides. [29] In addition, polarization of T cells to the T-helper cell type 1 (TH1) type is a well-recognized feature of CD, and emerging data indicate that TH17 cells also contribute to disease pathogenesis, whereas IL-23 receptor polymorphisms may confer protection from CD. [30, 31, 8]
It has also been proposed that neutrophil dysfunction may play a role in altered innate immunity early in the development of CD. [32, 33] At this point in time, the exact defects and mechanisms involved in disease pathogenesis are yet to be elucidated, and research is ongoing. Immunosuppression remains the mainstay of CD therapy, and it is likely that a combination of derangements that alter mucosal immunity and suppress immunoregulation is crucial in the development of this disease.
Unlike ulcerative colitis, Crohn disease (CD) can occur at any point along the gastrointestinal tract. The most commonly involved sites at presentation are the terminal ileum, ileocecal valve, and cecum.
Disease is limited to the small intestine in approximately 40-50% of cases, whereas another 30-40% of cases involve both the small intestine and the colon. The remaining cases involve only the colon. [34]
Aphthoid ulcers in the mouth and anal fissures, skin tags, and abscesses are frequently seen, whereas involvement of the esophagus and stomach is much less common. [35, 36]
Extraintestinal features are common and include the following:
Ocular manifestations (uveitis, recurrent iritis, and episcleritis)
Dermal manifestations (erythema nodosum, pyoderma gangrenosum, and Sweet syndrome)
Inflammatory seronegative arthropathies (sacroiliitis, ankylosing spondylitis, psoriatic arthritis, and reactive arthritis) [37]
The liver and bile ducts can be also be involved; the incidence of primary sclerosing cholangitis is increased by approximately 10% in patients with a history of CD. [38]
Regardless of the location of disease, Crohn disease (CD) usually follows a chronic, indolent course and tends to relapse and remit. Patients commonly present with symptoms due to ileocecal inflammation, [39, 40] including the following:
Crampy, lower right quadrant or periumbilical pain that is often relieved by defecation – Some patients report more diffuse and constant pain.
Prolonged nonbloody diarrhea with accompanying weight loss and possible malabsorption syndromes – If the colon is involved, the diarrhea may contain blood, mucus, and pus.
Low-grade fever and feeling of general fatigue and malaise
In pediatric patients, unexplained growth failure in addition to the above symptoms
Chronic, transmural inflammation can lead to fissures in the bowel wall with ensuing fistulas and abscesses. Fistulas may develop between the bowel and other organs, including enteroenteric fistulas, enterogastric, enterovaginal, enterocutaneous, and enterovesical fistulas. These can present as feculent vomiting or vaginal discharge, frequent urinary tract infections, pneumouria, fecaluria, and feculent soiling of skin lesions. Fistulas are significantly more common in postsurgical patients, an important reason why surgical intervention is deferred in favor of medical intervention, whenever possible. Retroperitoneal, intraperitoneal, and perianal/perirectal abscesses are common.
A retrospective study evaluated the clinico-pathological characteristics of patients who underwent surgery due to stricturing or non-perineal fistulizing Crohn’s disease. The study concluded that no specific clinical feature was found to differentiate patients with the stricturing form of Crohn’s disease from the fistulizing form. However, the authors also add that histopathological analysis of the resected specimens revealed significant differences in some parameters between the two disease forms. The L3 localization (Montreal Classification) was detected significantly more often in the non-perineal fistulizing group than in the stricturing group. [41]
Patients may also present with symptoms of obstruction, including the following:
Cramping, borborygmus, and postprandial bloating due to edema of the bowel wall
Possible ensuing constipation and obstipation, as the bowel wall becomes chronically thickened and the lumen narrows
Occurrence of complete obstruction as the result of stricture formation and progressive bowel wall thickening
Extraintestinal features may involve the mouth, anus, eyes, skin, joints, liver, and bile ducts. Aphthoid ulcers and erosions of the mouth, anal fissures, abscesses, ulceration around stomas and skin tags are common features of the disease. Uveitis and episcleritis as well as pyoderma gangrenosum and constitutional eczema are also quite common. [42, 43] The arthropathies tend to be migratory and asymmetrical, and there may be an associated ankylosing spondylitis. [44, 45]
Liver function test abnormalities are common, but severe hepatic pathology such as pericholangitis and primary sclerosing cholangitis are not as clearly associated with Crohn disease as with ulcerative colitis. [38]
Patients with Crohn colitis are at increased risk to develop intraepithelial neoplasia, also known as dysplasia, and colonic adenocarcinoma. [46] Patients should begin periodic regular colonoscopic surveillance for dysplasia and carcinoma beginning approximately 8-10 years after the diagnosis of Crohn colitis. Patients with concomitant primary sclerosing cholangitis are thought to be at increased risk for colorectal neoplasia compared with other Crohn patients, but the relative risk is better defined for patients with ulcerative colitis and primary sclerosing cholangitis. [47] In addition, strictures may harbor malignancy.
The biopsy strategy for surveillance includes 4-quadrant biopsies taken at intervals of every 10 cm of colon involved by the colitis, beginning 10 cm proximal to the area of involvement, and extending 10 cm distally. If there is pancolitis, at least 33 biopsies are recommended, and biopsies at 5-cm intervals of the rectum are included. Biopsies should also include any nodules or masses, as well as the flat mucosa adjacent to the masses, clearly designated as such, and submitted separately. [46]
NOTE: Extreme care should be taken to avoid labeling the patient with Crohn disease at first biopsy. It is preferable in this clinical context to provide a descriptive diagnosis with a differential diagnosis. Appropriate clinical follow-up and subsequent biopsies will usually resolve the diagnostic dilemma.
Rigid thickening of the involved segment of bowel wall is typical in Crohn disease, as seen in the image below.
Hyperplasia of the subserosal and mesenteric adipose tissue, leading to the appearance of “creeping fat,” is highly characteristic of the serosal surface of the specimen (see the following image). Serosal fibrosis, congestion, and adhesions are also common. [48, 49, 50]
Strictures, especially single, long segment strictures in the terminal ileum (leading to the string sign of Kantor on computed tomography [CT] scan) are classic, but multiple shorter strictures can also be seen. [29] See the image below.
The mucosal surface shows patchy lesional distribution with sharply delineated areas of disease surrounded by normal mucosa. Even in extensive disease, there are nearly always intervening patches of normal bowel with careful examination. In addition, linear and serpiginous mucosal ulcers with intervening mucosal edema lead to a classic gross “cobblestoned” appearance of the mucosa, as shown in the images below.
Deep ulcers, vertical fissures, and fistula tracts are commonly seen. In particular, vertical fissuring can be especially helpful in the distinction between Crohn disease and ulcerative colitis. [48] In addition, small, pinpoint hemorrhages and shallow ulcers with white bases (aphthoid ulcers) are frequent along the periphery of the involved segments of mucosa. [51]
The microscopic findings of Crohn disease (CD) can be highly variable. It is unusual to see all characteristic histopathologic features in a given case. [52, 48, 51]
Many of the classic microscopic findings were described in cases of bowel resection and in an era before the advent of immunosuppressive therapy. Pathologists currently face the challenge of rendering a pathologic diagnosis based on limited superficial mucosal biopsy samples obtained at endoscopy, often in the setting of previous treatment with anti-inflammatory medications.
The following are the most characteristic classically described histologic findings:
Areas of chronic inflammation, comprising increased lamina propria plasma cells and lymphocytes, in association with chronic architectural distortion with patchy, mild to severe, neutrophilic inflammation, including neutrophilic cryptitis, crypt abscesses, or erosions/ulcers
Skip lesions comprising focal, patchy erosions or ulcers, vertical fissures, and fistulas
The hint of “skip lesions” – Mucosal fragments from the same level of the colon have variable microscopic findings.
Transmural inflammation with multiple lymphoid aggregates
Granulomas
Submucosal fibrosis and neuromuscular hyperplasia of submucosa
The fissures are often longitudinally oriented, knifelike clefts lined by granulation tissue, epithelioid histiocytes, and giant cells, as depicted in the following images.
Focal, transmural inflammation consisting of lymphocytes, plasma cells, and neutrophils with large lymphoid aggregates is classic for CD. Cryptitis and crypt abscesses are common. The lymphoid aggregates are usually noted in the mucosa and submucosa, although they can be located throughout the bowel wall and are characteristically seen in the subserosal fat, following the vasculature. [53] See the images below.
The granulomas consist of non-necrotizing, well-circumscribed groups of epithelioid histiocytes, with or without accompanying giant cells of the Langerhans type (see the following images). [54] When present, granulomas are extremely helpful in securing the diagnosis of CD, but they are absent in 50-60% of cases. Moreover, granulomas are also seen in tuberculosis, yersiniosis, and can even be seen in ulcerative colitis in association with ruptured crypts. In general, caution must be employed when using granulomas as a diagnostic feature.
The granulomas of CD can be found throughout the bowel wall, and they are commonly associated with areas of ulcer, or along lymphatic spaces in the submucosa and subserosa, and, less frequently, with small blood vessels. [55, 56]
Granulomas are more commonly seen in the large bowel and anal region than in the small intestine; they are also more prominent in younger patients with a shorter disease duration than in patients with longstanding disease. [55]
Lymph nodes in the mesentery will often contain similar granulomas, but it is exceptional for granulomas to be present only in lymph nodes (see the image below). An alternate diagnosis should be strongly considered in such cases. [57]
Bowel wall thickening consisting of edema and fibrosis leading to splaying of the muscularis mucosae and distortion of the muscularis propria is present in CD (see the following image). Lymphangiectasia in the submucosa and subserosa is frequently observed as well.
Microscopic skipping of lesions is the cornerstone of CD diagnosis, especially in the absence of granulomas. Even in areas with extensive inflammation, there is usually adjacent, uninvolved bowel tissue, and recognition of this feature can assist with the diagnosis. Early lesions often demonstrate focal mucosal inflammation superficial to lymphoid aggregates or Peyer patches, only later developing into the characteristic aphthoid ulcers (see the following image). [51]
Although not specific to CD, pseudopyloric metaplasia (ulcer-associated cell lineage [UACL]) and villous architectural distortion are often seen in the small intestine. The UACL is thought to signify previous or concurrent ulceration as the pseudopyloric cells may secrete growth factors such as epidermal growth factor (EGF) that aid in mucosal healing. [58, 59]
Muscularization of the fibrotic submucosa and crypt architectural disorganization are features of chronic and so-called “burned out” CD and may be the only remaining evidence of disease in certain cases. See the image below.
The presence of intraepithelial neoplasia must be noted, and it should be categorized as low grade or high grade. If there is cytologic atypia in association with neutrophilic inflammation, the findings may represent repair or regeneration, and the case may be better categorized as “indefinite for dysplasia.” [60]
Immunohistochemistry has a minimal role, at most, in the diagnosis of Crohn disease (CD). Immunohistochemical stains for cytomegalovirus may be useful when a patient experiences a flare of disease while on immunosuppressive therapy—to exclude reactivation of latent viral infection or new viral infection as a cause of the inflammation. It is useful for the clinician to provide the pathologist with information regarding this concern, when applicable, to prompt consideration of special staining.
Several conditions should be considered when evaluating a patient for Crohn disease. These are discussed below, as follows:
Crohn disease versus ulcerative colitis
Infectious disease
Drugs-induced colitis
Conditions with small bowel fissuring ulcers
Diverticular disease
Ischemic changes
The main differential diagnosis is between Crohn disease (CD) and ulcerative colitis (UC). The distinction between these 2 conditions is important, as both increase the risk of developing adenocarcinoma, and the response to surgical treatment vary dramatically between them. [61, 62]
Although CD and UC each carry an increased risk of neoplastic transformation, the risk is higher and surgical intervention is better tolerated in UC. In CD, as noted earlier, there is a higher risk of recurrence and ulceration, fissure, and fistula formation at sites of reanastomosis or stoma formation. [63, 64]
The main features of CD that separate it from UC include the presence of skip lesions, granulomas, transmural inflammation, fissures, and/or involvement of any part of the gastrointestinal tract. UC is generally limited to the colon, apart from minimal distal “back-wash” ileitis; however, this condition may also manifest cecal or appendiceal patches of involvement that can simulate the “skip” lesions of CD. More typically, ulcerative colitis in its untreated state is a continuous process, worse distally, with increased span of involvement distal to proximal, as the disease progresses. Moreover, ulcerative colitis usually involves only the mucosal layer of the bowel, and, in some cases, superficial submucosa, unless there is fulminant colitis (toxic megacolon).
Nonetheless, the distinction between the 2 processes can be challenging, as CD can occasionally affect only the distal colon, granulomas may be present in UC (although typically adjacent to ruptured crypts, whereas CD granulomas have no necessary spatial relationship to injured crypts), and the regional involvement/skip lesions of CD may not be apparent endoscopically or in small mucosal biopsies. [52]
In addition, treatment can markedly alter the apparent pattern of involvement by location. For example, steroid enema treatment of UC may eradicate endoscopic and histologic evidence of rectal injury and inflammation, leaving more severe inflammation in the proximal colon. Without complete clinical information regarding the endoscopic appearance and the history of treatment, the pathologist may misconstrue the biopsy findings and render an incorrect diagnosis.
When the distinction between CD and UC is impossible, some pathologists choose to render a diagnosis of “indeterminate colitis.” [52, 65, 66, 67] In time, most cases will declare themselves as CD or UC, but approximately 30% may remain indeterminate. [52, 65]
It is critical for the pathologist and the managing physician to recognize that “indeterminate colitis” is not a third category of disease, but that it is a diagnosis of idiopathic inflammatory bowel disease (IIBD), not otherwise specified, pending additional information. Features that assist in defining CD in this setting are the presence of granulomas, transmural lymphoid aggregates, and creeping fat; however, these findings may be noted only in resection specimens. [68] Classification of the type of IIBD may be possible with additional clinical history, with biopsies of small intestine or stomach, or with disease recurrence and progression.
Infectious etiologies, especially yersiniosis and tuberculosis, can lead to a similar clinical and histopathologic picture as Crohn disease (CD) and must be considered. [39, 69, 57, 62] This is particularly important, given the risk for systemic infection if the patient is placed on immunosuppressive treatment for presumed CD. Therefore, it is strongly recommended that the endoscopic and managing physicians consider special studies, including special histologic stains for microorganisms, and even including polymerase chain reaction (PCR), to exclude infection, if there is any significant travel or exposure history, even remote.
Conversely, early or treated CD may manifest regionally as microscopic disease (focal active colitis) in a pattern otherwise typical of infectious or so-called “acute self-limited colitis.”
Drug-induced colitis—particularly nonsteroidal anti-inflammatory drug (NSAID) toxicity, methyldopa, gold, and penicillins—can produce mucosal changes that lead to full-thickness ulcers and resultant chronic crypt architectural remodeling that can mimic Crohn disease. Drugs may also cause a granulomatous reaction. [57, 70]
Fissuring ulcers in the small intestine may also be seen in Behçet disease, malignant lymphoma, and “ulcerative jejunitis.” The latter represents early lymphomatous transformation in celiac sprue. [29, 57]
Diverticular disease may be associated with active crypt injury in peridiverticular mucosa in a pattern that is indistinguishable from active Crohn disease (CD). Concomitant active or active chronic injury in nearby mucosa unassociated with diverticular ostia favors a diagnosis of CD.
Crohnlike changes, including erosions, fistulae, granulomas, crypt architectural distortion, and intraepithelial neutrophilic inflammation, may be seen in the vicinity of diverticulitis. Caution should be used in making a diagnosis of CD in the sigmoid colon or in the vicinity of diverticular disease, unless there is evidence of Crohnlike histologic changes in parts of the bowel uninvolved by diverticula. [71]
Ischemia may result in histologic changes that mimic Crohn disease, including full-thickness mucosal ulcerations and injury, with crypt architectural remodeling and pseudopyloric metaplasia, also known as “ulcer-associated changes” or “ulcer-associated cell lineage” (UACL).
Crohn BB, Ginzburg L, Oppenheimer GD. Landmark article Oct 15, 1932. Regional ileitis. A pathological and clinical entity. By Burril B. Crohn, Leon Ginzburg, and Gordon D. Oppenheimer. JAMA. 1984 Jan 6. 251(1):73-9. [Medline].
Lockhart-Mummery HE, Morson BC. Crohn’s disease of the large intestine. Gut. 1964 Dec. 5:493-509. [Medline]. [Full Text].
Feakins RM. Ulcerative colitis or Crohn’s disease? Pitfalls and problems. Histopathology. 2014 Feb. 64(3):317-35. [Medline].
CDC. Epidemiology of the IBD. Centers for Disease Control and Prevention. March 31, 2015. Available at https://www.cdc.gov/ibd/ibd-epidemiology.htm. Accessed: April 4, 2017.
Ye Y, Pang Z, Chen W, Ju S, Zhou C. The epidemiology and risk factors of inflammatory bowel disease. Int J Clin Exp Med. 2015. 8(12):22529-42. [Medline].
Kenny EE, Pe’er I, Karban A, et al. A genome-wide scan of Ashkenazi Jewish Crohn’s disease suggests novel susceptibility loci. PLoS Genet. 2012. 8(3):e1002559. [Medline].
Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998 Jul. 115(1):182-205. [Medline].
Kim DH, Cheon JH. Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies. Immune Netw. 2017 Feb. 17(1):25-40. [Medline].
Farmer RG, Michener WM, Mortimer EA. Studies of family history among patients with inflammatory bowel disease. Clin Gastroenterol. 1980 May. 9(2):271-7. [Medline].
Satsangi J, Parkes M, Jewell DP. Molecular genetics of Crohn’s disease: recent advances. Eur J Surg. 1998 Dec. 164(12):887-91. [Medline].
Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001 May 31. 411(6837):599-603. [Medline].
Meinzer U, Hugot JP. Nod2 and Crohn’s disease: many connected highways. Lancet. 2005 May 21-27. 365(9473):1752-4. [Medline].
Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008 Aug. 40(8):955-62. [Medline]. [Full Text].
Lesage S, Zouali H, Colombel JF, et al. Genetic analyses of chromosome 12 loci in Crohn’s disease. Gut. 2000 Dec. 47(6):787-91. [Medline]. [Full Text].
Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature. 1996 Feb 29. 379(6568):821-3. [Medline].
Cummings JR, Cooney R, Pathan S, et al. Confirmation of the role of ATG16L1 as a Crohn’s disease susceptibility gene. Inflamm Bowel Dis. 2007 Aug. 13(8):941-6. [Medline].
Massey DC, Parkes M. Genome-wide association scanning highlights two autophagy genes, ATG16L1 and IRGM, as being significantly associated with Crohn’s disease. Autophagy. 2007 Nov-Dec. 3(6):649-51. [Medline].
Cummings JR, Ahmad T, Geremia A, et al. Contribution of the novel inflammatory bowel disease gene IL23R to disease susceptibility and phenotype. Inflamm Bowel Dis. 2007 Sep. 13(9):1063-8. [Medline].
Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn’s disease susceptibility. Nat Genet. 2007 Jul. 39(7):830-2. [Medline]. [Full Text].
Cooper JG, Purcell GP. Data mining for correlations between diet and Crohn’s disease activity. AMIA Annu Symp Proc. 2006. 897. [Medline]. [Full Text].
Weinstock JV, Elliott DE. Helminths and the IBD hygiene hypothesis. Inflamm Bowel Dis. 2009 Jan. 15(1):128-33. [Medline].
De Hertogh G, Geboes K. Crohn’s disease and infections: a complex relationship. MedGenMed. 2004 Aug 10. 6(3):14. [Medline]. [Full Text].
Travis SP. Mycobacteria on trial: guilty or innocent in the pathogenesis of Crohn’s disease?. Eur J Gastroenterol Hepatol. 1995 Dec. 7(12):1173-6. [Medline].
Van Kruiningen HJ. Lack of support for a common etiology in Johne’s disease of animals and Crohn’s disease in humans. Inflamm Bowel Dis. 1999 Aug. 5(3):183-91. [Medline].
Ekbom A, Daszak P, Kraaz W, Wakefield AJ. Crohn’s disease after in-utero measles virus exposure. Lancet. 1996 Aug 24. 348(9026):515-7. [Medline].
Morris DL, Montgomery SM, Thompson NP, Ebrahim S, Pounder RE, Wakefield AJ. Measles vaccination and inflammatory bowel disease: a national British Cohort Study. Am J Gastroenterol. 2000 Dec. 95(12):3507-12. [Medline].
Thompson NP, Montgomery SM, Pounder RE, Wakefield AJ. Is measles vaccination a risk factor for inflammatory bowel disease?. Lancet. 1995 Apr 29. 345(8957):1071-4. [Medline].
Wakefield AJ, Ekbom A, Dhillon AP, Pittilo RM, Pounder RE. Crohn’s disease: pathogenesis and persistent measles virus infection. Gastroenterology. 1995 Mar. 108(3):911-6. [Medline].
Day DW, Jass JR, Price AB, et al. Morson and Dawson’s Gastrointestinal Pathology. 4th ed. Malden, Mass: Blackwell Science Ltd; 2003.
Brand S. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut. 2009 Aug. 58(8):1152-67. [Medline].
Kobayashi T, Okamoto S, Hisamatsu T, et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut. 2008 Dec. 57(12):1682-9. [Medline].
Korzenik JR, Dieckgraefe BK. Is Crohn’s disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn’s disease. Dig Dis Sci. 2000 Jun. 45(6):1121-9. [Medline].
Korzenik JR. Is Crohn’s disease due to defective immunity?. Gut. 2007 Jan. 56(1):2-5. [Medline]. [Full Text].
Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005 Sep. 19 Suppl A:5-36. [Medline].
Turner D, Griffiths AM. Esophageal, gastric, and duodenal manifestations of IBD and the role of upper endoscopy in IBD diagnosis. Curr Gastroenterol Rep. 2009 Jun. 11(3):234-7. [Medline].
Geboes K, Janssens J, Rutgeerts P, Vantrappen G. Crohn’s disease of the esophagus. J Clin Gastroenterol. 1986 Feb. 8(1):31-7. [Medline].
Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006 Aug 14. 12(30):4819-31. [Medline].
Eade MN, Cooke WT, Williams JA. Liver disease in Crohn’s disease. A study of 100 consecutive patients. Scand J Gastroenterol. 1971. 6(3):199-204. [Medline].
Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinical features and natural history of Crohn’s disease. Gastroenterology. 1979 Oct. 77(4 Pt 2):898-906. [Medline].
Farmer RG, Hawk WA, Turnbull RB Jr. Clinical patterns in Crohn’s disease: a statistical study of 615 cases. Gastroenterology. 1975 Apr. 68(4 Pt 1):627-35. [Medline].
Cayci M, Bostanci EB, Turhan N, et al. The analysis of clinico-pathologic characteristics in patients who underwent surgery due to stricturing and non-perineal fistulizing forms of Crohn’s disease: a retrospective cohort study. Int J Surg. 2015 Mar. 15:49-54. [Medline].
Burgdorf W. Cutaneous manifestations of Crohn’s disease. J Am Acad Dermatol. 1981 Dec. 5(6):689-95. [Medline].
Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore). 1976 Sep. 55(5):401-12. [Medline].
Enlow RW, Bias WB, Arnett FC. The spondylitis of inflammatory bowel disease. Evidence for a non-HLA linked axial arthropathy. Arthritis Rheum. 1980 Dec. 23(12):1359-65. [Medline].
Ferguson RH. Arthritis associated with inflammatory bowel disease. Minn Med. 1981 Mar. 64(3):165-6. [Medline].
Itzkowitz SH. Inflammatory bowel disease and cancer. Gastroenterol Clin North Am. 1997 Mar. 26(1):129-39. [Medline].
Brentnall TA, Haggitt RC, Rabinovitch PS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 1996 Feb. 110(2):331-8. [Medline].
Morson BC. Pathology of Crohn’s disease. Ann R Coll Surg Engl. 1990 May. 72(3):150-1. [Medline]. [Full Text].
Desreumaux P, Ernst O, Geboes K, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn’s disease. Gastroenterology. 1999 Jul. 117(1):73-81. [Medline].
Sheehan AL, Warren BF, Gear MW, Shepherd NA. Fat-wrapping in Crohn’s disease: pathological basis and relevance to surgical practice. Br J Surg. 1992 Sep. 79(9):955-8. [Medline].
Morson BC. The early histological lesion of Crohn’s disease. Proc R Soc Med. 1972 Jan. 65(1):71-2. [Medline]. [Full Text].
Yantiss RK, Odze RD. Diagnostic difficulties in inflammatory bowel disease pathology. Histopathology. 2006 Jan. 48(2):116-32. [Medline].
Morson BC. Histopathology of Crohn’s disease. Scand J Gastroenterol. 1971. 6(7):573-5. [Medline].
Chambers TJ, Morson BC. The granuloma in Crohn’s disease. Gut. 1979 Apr. 20(4):269-74. [Medline]. [Full Text].
Mooney EE, Walker J, Hourihane DO. Relation of granulomas to lymphatic vessels in Crohn’s disease. J Clin Pathol. 1995 Apr. 48(4):335-8. [Medline]. [Full Text].
Wakefield AJ, Sankey EA, Dhillon AP, et al. Granulomatous vasculitis in Crohn’s disease. Gastroenterology. 1991 May. 100(5 Pt 1):1279-87. [Medline].
Shepherd NA. Pathological mimics of chronic inflammatory bowel disease. J Clin Pathol. 1991 Sep. 44(9):726-33. [Medline]. [Full Text].
Hanby AM, Wright NA. The ulcer-associated cell lineage: the gastrointestinal repair kit?. J Pathol. 1993 Sep. 171(1):3-4. [Medline].
Wright NA, Pike C, Elia G. Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in human gastrointestinal stem cells. Nature. 1990 Jan 4. 343(6253):82-5. [Medline].
Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983 Nov. 14(11):931-68. [Medline].
Farmer M, Petras RE, Hunt LE, Janosky JE, Galandiuk S. The importance of diagnostic accuracy in colonic inflammatory bowel disease. Am J Gastroenterol. 2000 Nov. 95(11):3184-8. [Medline].
Geboes K. Crohn’s disease, ulcerative colitis or indeterminate colitis–how important is it to differentiate?. Acta Gastroenterol Belg. 2001 Apr-Jun. 64(2):197-200. [Medline].
Haggitt RC, Appelman HD, Correa P, et al. Carcinoma or dysplasia in Crohn’s disease. Arch Pathol Lab Med. 1982 Jun. 106(6):308-9. [Medline].
Ullman T, Odze R, Farraye FA. Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn’s disease of the colon. Inflamm Bowel Dis. 2009 Apr. 15(4):630-8. [Medline]. [Full Text].
Geboes K, De Hertogh G. Indeterminate colitis. Inflamm Bowel Dis. 2003 Sep. 9(5):324-31. [Medline].
Geboes K, Colombel JF, Greenstein A, et al. Indeterminate colitis: a review of the concept–what’s in a name?. Inflamm Bowel Dis. 2008 Jun. 14(6):850-7. [Medline].
Guindi M, Riddell RH. Indeterminate colitis. J Clin Pathol. 2004 Dec. 57(12):1233-44. [Medline]. [Full Text].
Geboes K, Van Eyken P. Inflammatory bowel disease unclassified and indeterminate colitis: the role of the pathologist. J Clin Pathol. 2009 Mar. 62(3):201-5. [Medline].
Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002 Aug 8. 347(6):417-29. [Medline].
Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med. 1992 Sep 10. 327(11):749-54. [Medline].
Goldstein NS, Leon-Armin C, Mani A. Crohn’s colitis-like changes in sigmoid diverticulitis specimens is usually an idiosyncratic inflammatory response to the diverticulosis rather than Crohn’s colitis. Am J Surg Pathol. 2000 May. 24(5):668-75. [Medline].
Kirsner JB, Shorter RG. Recent developments in nonspecific inflammatory bowel disease (second of two parts). N Engl J Med. 1982 Apr 8. 306(14):837-48. [Medline].
Mayberry JF, Rhodes J. Epidemiological aspects of Crohn’s disease: a review of the literature. Gut. 1984 Aug. 25(8):886-99. [Medline]. [Full Text].
Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010 Feb. 138(2):746-74, 774.e1-4; quiz e12-3. [Medline].
Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010 Feb. 138(2):738-45. [Medline].
Bressenot A, Geboes K, Vignaud JM, Gueant JL, Peyrin-Biroulet L. Microscopic features for initial diagnosis and disease activity evaluation in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Jul. 19(8):1745-52. [Medline].
Mara Rendi, MD, PhD Acting Assistant Professor, Department of Anatomic Pathology, University of Washington School of Medicine
Disclosure: Nothing to disclose.
Paul E Swanson, MD, FCAP Clinical Professor of Pathology, University of Calgary Faculty of Medicine; Director of Immunohistochemistry, Calgary Laboratory Services
Paul E Swanson, MD, FCAP is a member of the following medical societies: American Society for Clinical Pathology, Arthur Purdy Stout Society, College of American Pathologists, United States and Canadian Academy of Pathology
Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: College of American Pathologists<br/>Received consulting fee from ASCP for assistant editor ajcp.
Melissa P Upton, MD Associate Professor of Pathology, University of Washington School of Medicine; Associate Director, Anatomic Pathology Division, Director, Rodger C Haggitt Gastroenterologic and Hepatic Pathology Service, University of Washington Medical Center
Melissa P Upton, MD is a member of the following medical societies: American Society for Investigative Pathology, American Society for Clinical Pathology, College of American Pathologists, United States and Canadian Academy of Pathology, Transplantation Society, Hans Popper Hepatopathology Society, World Organization for Specialized Studies on Diseases of the Esophagus, Pacific Northwest Society of Pathologists
Disclosure: Nothing to disclose.
Mamoun Younes, MD Professor of Pathology, Director of Gastrointestinal and Liver Pathology Service, University of Texas Health Science Center at Houston, McGovern Medical School
Mamoun Younes, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, American Society of Clinical Oncology, College of American Pathologists, United States and Canadian Academy of Pathology
Disclosure: Nothing to disclose.
Crohn Disease Pathology
Research & References of Crohn Disease Pathology|A&C Accounting And Tax Services
Source
0 Comments